A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.